imidazo[1,2-a]quinazoline | 235-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: imidazo[1,2-a]quinazoline
• CAS: 235-16-5
• 化学式: C₁₀H₇N₃
• 分子量: 169.186
• InChiKey: VYWVDWXJIWSMJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  邻硝基苯甲醛 、 2-氨基咪唑硫酸盐 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以69%的产率得到imidazo[1,2-a]quinazoline
  参考文献：
  名称：

  One-Pot Synthesis of Benzo[4,5]imidazo[1,2-a]quinazoline Derivatives via Facile Transition-Metal-Free Tandem Process

  摘要：

  A one-pot transition metal-free method for synthesizing benzo[4,5]imidazo[1,2-a]quinazoline and imidazo-[1,2-a]quinazoline derivatives has been developed. The approach is widely applicable to 2-fluoro-, 2-chloro-, 2-bromo- and 2-nitro-substituted aryl aldehyde and ketone substrates. The fluorescence properties of target compounds were studied.

  DOI：

  10.1021/co500001u

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150376233A1

  公开（公告）日：2015-12-31

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般式（I）的丙型肝炎病毒抑制剂。还公开了包含这些化合物的组合物和使用这些化合物抑制HCV的方法。
• TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
  申请人：Hutchinson John Howard

  公开号：US20070173508A1

  公开（公告）日：2007-07-26

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制5-脂氧合酶（5-LO）的活性。本文还描述了使用这种5-LO抑制剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的状况、疾病或紊乱。
• Hepatitis C Virus Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150284409A1

  公开（公告）日：2015-10-08

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般公式（I）的丙型肝炎病毒抑制剂。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• Use of STAT-6 inhibitors as therapeutic agents
  申请人：——

  公开号：US20030143199A1

  公开（公告）日：2003-07-31

  The present invention provides A therapeutic method to enhance the efficacy of interferon treatment comprising administering to a mammal subject to interferon treatment a compound which is an antagonist of the IL-4 or IL-13 signal transduction pathway in an amount effective to enhance said efficacy. The method includes treatment of diseases such as cancer, proliferative fibrotic diseases, viral diseases, or autoimmune diseases. The invention also includes the use of chemotherapeutic agents, radiation or other treatments in conjunction with the method of the invention.

  本发明提供了一种治疗方法，用于增强干扰素治疗的疗效，包括向接受干扰素治疗的哺乳动物主体施用一种拮抗IL-4或IL-13信号传导途径的化合物，其有效剂量能够增强该疗效。该方法包括治疗癌症、增生性纤维病性疾病、病毒性疾病或自身免疫疾病。该发明还包括与本发明方法结合使用化疗药物、放射线或其他治疗方法。
• BISCARBAZOLE DERIVATIVES AND ORGANIC ELECTROLUMINESCENCE
  申请人：Inoue Tetsuya

  公开号：US20120223295A1

  公开（公告）日：2012-09-06

  Provided are an organic electroluminescence device having high current efficiency and a long lifetime, and a biscarbazole derivative for realizing the device. The biscarbazole derivative has a specific substituent. The organic EL device has a plurality of organic thin-film layers including a light emitting layer between a cathode and an anode, and at least one layer of the organic thin-film layers contains the biscarbazole derivative.